Gateway Wealth Partners LLC Grows Stock Position in Amgen Inc. $AMGN

Gateway Wealth Partners LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 224.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,323 shares of the medical research company’s stock after buying an additional 2,989 shares during the quarter. Gateway Wealth Partners LLC’s holdings in Amgen were worth $1,521,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Cypress Capital Group raised its holdings in Amgen by 4.5% in the 1st quarter. Cypress Capital Group now owns 17,693 shares of the medical research company’s stock worth $6,225,000 after purchasing an additional 758 shares during the period. Everest Financial Group LLC bought a new stake in Amgen during the first quarter valued at about $530,000. OMERS ADMINISTRATION Corp increased its position in Amgen by 23.1% in the first quarter. OMERS ADMINISTRATION Corp now owns 41,398 shares of the medical research company’s stock worth $14,566,000 after buying an additional 7,765 shares in the last quarter. Van Diest Capital LLC purchased a new stake in Amgen in the first quarter worth about $586,000. Finally, Lombard Odier Asset Management Switzerland SA raised its stake in shares of Amgen by 10.2% in the first quarter. Lombard Odier Asset Management Switzerland SA now owns 41,283 shares of the medical research company’s stock worth $14,525,000 after buying an additional 3,811 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Investor attention around AMGN has increased, potentially supporting trading interest as the company approaches its second-quarter results. Amgen investor attention article
• Neutral Sentiment: Amgen will release its second-quarter 2026 financial results after the U.S. market closes on August 4 and host an investor conference call at 4:30 p.m. ET. The announcement gives investors a near-term catalyst, with management expected to discuss results and outlook. Amgen second-quarter webcast announcement
• Negative Sentiment: An earnings preview projects that Amgen’s second-quarter earnings may decline and suggests the company lacks the factors typically associated with a likely earnings beat. That could weigh on expectations ahead of the August 4 report. Amgen Q2 earnings preview
• Negative Sentiment: Amgen halted a late-stage Phase 3 study of rocatinlimab in prurigo nodularis, resetting expectations for the drug in dermatology. The development removes or delays a potential source of future growth and adds uncertainty to the company’s pipeline. Rocatinlimab Phase 3 study article

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. UBS Group boosted their price objective on Amgen from $400.00 to $420.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Guggenheim lifted their price target on shares of Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a report on Monday, July 13th. BMO Capital Markets reiterated an “outperform” rating and issued a $400.00 price target on shares of Amgen in a research report on Wednesday, July 1st. Weiss Ratings cut shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 15th. Finally, Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $356.62.

Amgen Stock Up 4.5%

NASDAQ AMGN opened at $393.10 on Wednesday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $398.00. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a market cap of $212.16 billion, a PE ratio of 27.36, a P/E/G ratio of 3.81 and a beta of 0.41. The stock’s 50 day moving average is $353.56 and its 200 day moving average is $352.71.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the firm posted $4.90 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts predict that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.